Yousif Capital Management LLC Cuts Stake in Amedisys, Inc. (NASDAQ:AMED)

Yousif Capital Management LLC reduced its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 2.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,550 shares of the health services provider’s stock after selling 284 shares during the period. Yousif Capital Management LLC’s holdings in Amedisys were worth $1,070,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in AMED. Norges Bank acquired a new position in shares of Amedisys during the 4th quarter valued at about $83,061,000. Wealthfront Advisers LLC bought a new position in Amedisys during the fourth quarter worth $72,970,000. Pentwater Capital Management LP increased its position in Amedisys by 178.3% in the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock worth $107,132,000 after buying an additional 756,000 shares during the period. AQR Arbitrage LLC increased its holdings in shares of Amedisys by 59.1% during the fourth quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider’s stock valued at $42,812,000 after purchasing an additional 175,311 shares during the period. Finally, Birnam Oak Advisors LP acquired a new position in shares of Amedisys during the fourth quarter valued at $15,832,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMED. Wall Street Zen lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Finally, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $100.75.

Amedisys Stock Performance

AMED opened at $97.89 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.29 and a current ratio of 1.29. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The firm has a market cap of $3.21 billion, a P/E ratio of 36.12, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The business’s fifty day moving average is $94.41 and its 200-day moving average is $92.05.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The company had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. During the same period last year, the company earned $1.03 earnings per share. The firm’s revenue was up 4.1% compared to the same quarter last year. Sell-side analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.